Predictors of hemorrhagic complications after intravenous thrombolysis in acute cerebral infarction patients
A single-center study of 391 cases

Jianqi Zengab, Feng Chenb, Yiqian Chena, Muli Pengb, Xingyu Chena, Qingwei Yanga, Ru Wangc, Jiayin Miaoa,*

Abstract
For patients with ischemic stroke, intravenous (IV) thrombolysis with Urokinase within 6 hours has been accepted as beneficial, but its application is limited by high risk of hemorrhagic complications after thrombolysis. This study aimed to analyze the risk factors of hemorrhagic complications after intravenous thrombolysis using Urokinase in acute cerebral infarction (ACI) patients.

Total 391 consecutive ACI patients were enrolled and divided into 2 groups: the hemorrhagic complications group and the non-hemorrhagic complications group. The related data were collected and analyzed.

Univariate analysis showed significant differences in prothrombin time, atrial fibrillation (AF), Mean platelet volume, large platelet ratio (L-PLR), triglyceride (TG), Lactate dehydrogenase, alanine aminotransferase (ALT), high-density lipoprotein, and baseline National Institute of Health Stroke Scale score between the hemorrhagic complications and the non-hemorrhagic complications group (P < .1). Multivariate logistic regression analysis indicated that AF (odds ratio [OR] = 2.91, 95% confidence interval [CI] = 1.06–7.99 P = .039) was the risk factor of hemorrhagic complications, while ALT (OR = 0.27, 95% CI = 0.10–0.72 P = .009) and TG (OR = 0.16, 95% CI = 0.06–0.45 P = .000) were protective factors of hemorrhagic complications.

For patients with AF and lower levels of ALT or TG, the risk of hemorrhagic complications might increase after ACI.

Abbreviations: ACI = acute cerebral infarction, AF = atrial fibrillation, ALT = alanine aminotransferase, CT = computed tomography, IVT = intravenous thrombolysis, rt-PA = recombinant tissue plasminogen activator, TG = triglyceride.

Keywords: acute cerebral infarction, alanine aminotransferase, atrial fibrillation, hemorrhagic complications, triglyceride, urokinase

1. Introduction
Acute cerebral infarction (ACI) is the most common clinical cerebrovascular disease. ACI is caused by sudden arterial occlusion that blocks blood supply to the brain.1 In the past few decades, clinical trials have shown that patients who received intravenous thrombolysis had significantly reduced disability at 3 months compared with patients who received placebo.2,3 At present, the use of recombinant tissue plasminogen activator (rt-PA) intravenous thrombolysis in the treatment of ACI has become a clinical standard in the world.4 In developing countries such as China, Urokinase is used more frequently than rt-PA, mainly because rt-PA is not covered by medical insurance and Urokinase is cheaper.5 A limited number of studies performed with Urokinase have reported improvements in recanalization and neurological outcomes similar to those achieved with treatments with rt-PA.6,7 However, Urokinase intravenous thrombolysis has a risk of hemorrhage. Patients with severe hemorrhage usually have a poor prognosis, with a mortality rate as high as 90%.8 Up to now, most studies have focused on cerebral hemorrhage as a complication of intravenous thrombolysis. Although the symptoms of peripheral hemorrhage can affect the survival of patients after urokinase intravenous thrombolysis, few people discuss events related to peripheral hemorrhage.

Hemorrhagic complications include hemorrhagic transformation, gastrointestinal bleeding, urethral bleeding, skin and mucous membrane bleeding, and gum bleeding. In this study, we analyzed the predictors of hemorrhagic complications after urokinase
intravenous thrombolysis, which can predict the probability of hemorrhage before intravenous thrombolysis, and pay more attention to thrombolytic situation and prognosis of the patients.

2. Materials and methods

The study was approved by the ethics committee of the Zhaoqing Gaoyao People’s Hospital, and written informed consent was obtained from all patients. A total of 391 patients with ACI received Urokinase thrombolysis therapy from January 2013 to October 2019. Urokinase $150 \times 10^4$ U diluted with 100 mL saline for patients with weight more than 50 kg and $100 \times 10^4$ U for patients with weight less than 50 kg was injected intravenously within 1 hour. All patients were divided into a hemorrhagic complications group and a non-hemorrhagic complications group. Any hemorrhagic transformation was found by a head Magnetic Resonance Imaging or computed tomography (CT) scan after thrombolysis. Baseline patient information was collected including demographics, past-history, complications and the index of coagulation system and other blood test before intravenous thrombolysis (IVT).

The inclusion criteria were: patients suffered from ACI without coma within 6 hours; age range between 18 and 85 years old; low density ischemic lesions were not observed via head CT scanning with cerebral hemorrhage eliminated; not pregnant; and patient or family members sign informed consent form.

The exclusion criteria were: patients with single attack of transient ischemic attack, rapid improvement of stroke and minor functional impairment; patients with subarachnoid hemorrhage via past history and CT scanning; prolonged blood pressure elevation (systolic blood pressure $\geq 185$ mm Hg or diastolic blood pressure $\geq 110$ mm Hg); patients showed hemorrhage, brain edema, arteriovenous malformation and tumor via CT; patients with infective endocarditis; patients received anticoagulant or heparin within 48 hours before stroke; patients suffered from arterial puncture within 7 days, major surgery or trauma within 14 days, and active continuing hemorrhage; and patients with blood system diseases, hemorrhagic diathesis, and coagulation disorder; international normalized ratio $>1.5$; platelet $<100 \times 10^9/L$; Suffering from chronic diseases except hypertension, atrial fibrillation, diabetes. The flow chart for case selection was shown in Figure 1.

All the data were analyzed by SPSS V.19 version. Quantitative data in normal distribution were analyzed and compared by the t test between 2 groups. The enumeration data were analyzed using the Fisher exact test or the $\chi^2$ test. Logistic regression analysis was applied to analyze the influencing factors for hemorrhagic complications.
3. Results

Total 391 patients were enrolled in our study, including 354 (90.5%) in the non-hemorrhagic complications group (mean age 67.17 ± 12.45 years; 155 males/ratio 61.0%) and 37 in the hemorrhagic complications group (mean age 68.11 ± 10.76 years; 20 males/ratio 54.1%).

Univariate analysis showed that there were no significant differences between the 2 groups in basic information such as gender, past history, drinking history, smoking history, and hypertension. However, atrial fibrillation (AF) was 1 variable that was significantly different between hemorrhagic complications group and non-hemorrhagic complications group (Table 1).

By analyzing the clinical and biochemical data, we observed that prothrombin time, Mean platelet volume, platelet-larger cell ratio, Lactate dehydrogenase, high-density lipoprotein and baseline National Institute of Health Stroke Scale score were significantly increased, whereas alanine aminotransferase (ALT) and triglyceride (TG) were significantly reduced in hemorrhagic complications group compared with non-hemorrhagic complications group (Table 2).

Next, we analyzed these factors using multiple logistic regression, choosing the following parameters: AF, prothrombin time ≥13.05 second, mean platelet volume ≥9.55 fl, platelet-larger cell ratio ≥19.6%, Lactate dehydrogenase ≥180.5 IU/L, ALT ≥12.75 IU/L, TG ≥0.76 mmol/L, high-density lipoprotein ≥1.445 mmol/L, baseline National Institute of Health Stroke Scale score. The results showed that AF was risk factors and ALT and TG were the protective factors of hemorrhagic complications after IVT in acute cerebral infarction (Table 3).

4. Discussion

With continuous improvement of living conditions, ACI has become one of the most common diseases. However, ACI has high morbidity and mortality rate, which has become one of the major diseases that endanger human health. How to choose the best treatment has become a pivotal problem. At present, thrombolytic therapy has been the best intervention for ACI. Most patients who receive urokinase thrombolysis have a good prognosis, compared with patients not receiving IVT. However, hemorrhagic complication is one of the most serious complications of ACI. A total of 391 patients with ACI were included in this study, 37 of whom were confirmed to have hemorrhagic complications after IVT. These hemorrhagic complications include hemorrhagic transformation, gastrointestinal bleeding, urethral bleeding, skin and mucous membrane bleeding, and gum bleeding. Our study showed that the hemorrhagic complications rate was 9.4% after IVT, partially consistent with the results of previous studies.

AF is an important cause of ACI, due to the occlusion of cerebral blood vessels. Hemorrhagic complications occurs in up to 71% of cardioembolic strokes. The most commonly accepted explanation is that ACI is caused by the blockage of a large artery by the thrombus; this blockage then causes local vasospasm. The local vasospasm and fragmentation of the thrombus cause tissue ischemia, and damaged vessel walls and capillaries are exposed to reperfusion. This is consistent with our findings.

In this study, we found that ALT was a protective factor of hemorrhagic complications. It is well known that liver dysfunction is related to hemorrhage, perhaps due to the decrease of blood coagulation factor and platelets. According to previous studies, some liver function indicators play an important role in hemorrhagic complications. For example, alkaline phosphatase, bilirubin and gamma glutamyl transpeptidase may play a harmful role in the prognosis of hemorrhagic complications through aggravating inflammation reaction, damaging cerebral vessels or enlarging edema after stroke. However, other indicators such as ALT and aspartate aminotransferase were found to have neuroprotective effects and may improve the prognosis of hemorrhagic complications. In our clinical practice, decompensated liver disease is a contraindication to
have demonstrated a beneficial relationship between ALT and hemorrhagic complications after IVT. Therefore, for patients with mild change of liver function, the liver may affect the prognosis of hemorrhagic complications through liver function indicators. Glutamate would accumulate after ACI, and ALT could protect cerebral tissue by decreasing glutamate.[26,27] Indeed, previous studies would accumulate after ACI, and ALT could protect cerebral tissue by decreasing glutamate.[26,27] Indeed, previous studies have demonstrated a beneficial relationship between ALT and outcome after ACI.[26,28] Moreover, glutamic-oxaloacetic transaminase 1 is involved in glutamate metabolism in AF condition.[28] These results suggest that we can reduce the risk of hemorrhagic complications by reducing glutamate.

In addition, we found that TG lower than 0.76 mmol/L was associated with hemorrhagic complications. Some studies have shown inconsonant relationship between triglyceride and hemorrhagic complications risk.[30,31] One recent study reported that low triglyceride levels were related to increased risk of hemorrhagic complications.[32] The mechanism by which low triglyceride levels promote hemorrhagic complications is unclear. In stroke-prone rats low serum cholesterol levels led to low cholesterol in erythrocyte membrane, and abnormal erythrocyte membrane fragility may cause arterial necrosis in endothelial cells.[33] Furthermore, low cholesterol could promote cerebrovascular endothelial fragility.[34] The results of this study support these speculations.

This study has some limitations. First, this was a single-center retrospective study, the relatively small sample size might have caused some biases. Therefore, we should design prospective multi-center clinical trials with large sample size to confirm our results. Next, Urokinase used only in a few countries, it may cause racial bias. Third, we need explore the mechanisms by which these predictors cause hemorrhagic complications.

In conclusion, this study revealed some predictors of hemorrhagic transformation after IVT with Urokinase in ACI patients. In particular, patients with AF and lower levels of ALT or TG have increased risk of hemorrhagic complications after IVT with Urokinase. These patients should be given great attention during IVT treatment.

Author contributions

Conceptualization: Jianqi Zeng, Jiayin Miao.
Data curation: Yiqian Chen, Ru Wang.
Formal analysis: Feng Chen.

Table 2
Clinical and biochemical data of the patients in 2 groups.

| Variables | Non-hemorrhagic complications (n = 354) | Hemorrhagic complications (n = 37) | P value |
|-----------|----------------------------------------|-----------------------------------|--------|
| PT        | 12.80 (11.80–13.50)                    | 13.10 (12.40–13.85)              | .081   |
| APPT      | 33.60 (28.83–38.03)                    | 33.20 (29.60–37.80)              | .882   |
| TT        | 17.10 (16.20–18.10)                    | 17.25 (16.58–19.00)              | .347   |
| FB        | 3.34 (2.81–3.95)                       | 3.27 (2.97–3.94)                 | .931   |
| PLT       | 221.50 (188.00–262.00)                 | 216.00 (169.00–252.00)           | .130   |
| MPV       | 9.30 (8.70–10.00)                      | 9.80 (8.85–10.45)                | .058   |
| PDW       | 15.40 (10.70–15.90)                    | 15.20 (12.45–16.00)              | .645   |
| P-LCR     | 20.40 (16.60–24.93)                    | 22.60 (19.70–29.45)              | .030   |
| LDH       | 202.20 (169.00–234.25)                 | 222.50 (190.50–265.33)           | .022   |
| Cre       | 76.10 (66.00–92.00)                    | 76.50 (60.05–93.45)              | .556   |
| GLU       | 6.74 (5.74–8.25)                       | 7.17 (6.29–9.85)                 | .127   |
| GbH       | 5.80 (5.50–6.30)                       | 5.75 (5.53–6.08)                 | .830   |
| D-Dimer   | 404.00 (157.50–1011.00)                | 540.50 (230.25–1535.50)          | .290   |
| albumin   | 39.30 (35.68–42.21)                    | 40.06 (35.90–42.75)              | .066   |
| DBIL      | 4.00 (3.00–5.70)                       | 4.50 (3.10–7.70)                 | .247   |
| I-Bil     | 8.50 (6.00–11.30)                      | 9.20 (6.85–11.85)                | .763   |
| ALT       | 16.00 (12.40–23.10)                    | 13.10 (8.75–20.10)               | .065   |
| AST       | 21.80 (17.38–26.23)                    | 22.80 (19.50–28.60)              | .189   |
| γ-GT      | 25.25 (19.00–39.00)                    | 28.00 (20.60–40.00)              | .766   |
| TG        | 1.20 (0.90–1.69)                       | 0.75 (0.57–1.20)                 | <.001* |
| TCHO      | 5.01 (4.19–5.92)                       | 4.93 (3.97–5.55)                 | .438   |
| HDL       | 11.80 (10.30–1.48)                     | 1.47 (1.13–1.64)                 | .026   |
| LDL       | 3.00 (2.37–3.74)                       | 2.81 (2.10–3.48)                 | .275   |
| UA        | 346.60 (291.78–422.40)                 | 344.30 (279.30–396.60)           | .763   |
| baseline NIHSS score | 7 (4–10)                  | 10 (7–16)                  | <.001* |

Values are median (IQR). γ-GT = γ-glutamyl transpeptidase, ALT = alanine aminotransferase, APPT = activated partial thromboplastin time, AST = aspartate aminotransferase, Cre = creatinine, DBIL = direct bilirubin, FB = fibrinogen, GbH = glycated hemoglobin, GLU = blood glucose, HDL = high-density lipoprotein, I-Bil = indirect bilirubin, LDH = lactate dehydrogenase, LDL = low-density lipoprotein, MPV = mean platelet volume, NIHSS = baseline National Institute of Health Stroke Scale, PDW = platelet distribution width, P-LCR = platelet-larger cell ratio, PT = prothrombin time, TCHO = total cholesterol, TG = triglyceride, TT = thrombin time, UA = uric acid.

* P < .1.

Table 3
Logistic regression analysis of influencing factors of hemorrhagic complications.

| Variables | OR   | 95% CI | P value |
|-----------|------|--------|--------|
| AF        | 2.91 | 1.06–7.99 | .039*  |
| PT ≥13.05 | 0.97 | 0.35–2.69 | .959   |
| MPV ≥ 9.95 | 1.47 | 0.93–5.49 | .568   |
| P-LCR ≥ 19.6 | 2.04 | 0.49–8.58 | .329   |
| LDH ≥ 180.5 | 1.78 | 0.51–6.23 | .367   |
| ALT ≥12.75 | 0.27 | 0.10–0.72 | .009*  |
| TG ≥0.76  | 0.16 | 0.06–0.45 | .000*  |
| HLD ≥1.445 | 1.20 | 0.44–3.24 | .725   |
| baseline NIHSS score ≥6.5 | 2.27 | 0.77–6.73 | .137   |

AF = atrial fibrillation, ALT = alanine aminotransferase, HDL = high-density lipoprotein, LDH = lactate dehydrogenase, MPV = mean platelet volume, NIHSS = baseline National Institute of Health Stroke Scale, P-LCR = platelet-larger cell ratio, PT = prothrombin time, TG = triglyceride.

* P < .05.
Funding acquisition: Jiayin Miao.
Investigation: Feng Chen, Xingyu Chen, Ru Wang.
Methodology: Xingyu Chen, Jiayin Miao.
Project administration: Qingwei Yang.
Resources: Qingwei Yang.
Software: Yiqian Chen, Muli Peng.
Validation: Muli Peng.
Visualization: Muli Peng.
Writing – original draft: Jianqi Zeng.
Writing – review & editing: Jiayin Miao.

References

[1] Zhang B, Yang N, Lin SP, Zhang F. Suitable concentrations of uric acid can reduce cell death in models of OGD and cerebral ischemia–reperfusion injury. Cellular Mol Neurobiol 2016;37:1–9.

[2] Cordonnier C, Al-Shahi Salman R, Wardlaw J. Spontaneous brain microbleeds: systematic review, subgroup analyses and standards for study design and reporting. Brain J Neurol 1308:1988–2003.

[3] Rowe AS, Greene CL, Snider CC, et al. Thromboelastographic changes in patients experiencing an acute ischemic stroke and receiving alteplase. J Stroke Cerebrovasc Dis 2014;23:1307–11.

[4] Wozniak AW. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004;13:19.

[5] Yuan Z, Wang B, Li F, et al. Intravenous thrombolysis guided by a telemedicine consultation system for acute ischemic stroke patients in China: the protocol of a multicentre historically controlled study. BMJ Open 2015:9.

[6] Ogawa A, Mori E, Minematsu K, et al. Randomized trial of intraarterial infusion of urokinase within 6 hours of middle cerebral artery stroke: the middle cerebral artery embolism local fibrinolytic intervention trial (MELT) Japan. Stroke 2007;38:2633.

[7] Wang L, Jia C, Zhang Y. The comparative study on therapeutic effects of intravenous alteplase thrombolysis, intravenous urokinase thrombolysis and interventional urokinase thrombolysis for acute ischemic stroke. Int J Clin Exp Med 2017;10:13646–52.

[8] Yang N, Lin M, Wang BG, Zeng WY, Zhong Y. Low level of low-density lipoprotein cholesterol is related with increased hemorrhagic transformation after acute ischemic cerebral infarction. Eur Rev Med Pharmacol Sci 2016;20:673–8.

[9] Sun G, Gao Z, Gao J. Intravenous thrombolysis with low dose urokinase for acute cerebral infarctions. Chin J Pract Nervous Dis 2011.

[10] Liu B, Zhang H, Wang R, Qu H, Zhang S. Early administration of tiroziban after urokinase-mediated intravenous thrombolysis reduces early neurological deterioration in patients with branch atheromatous disease. J Int Med Res 2020;48:3006052092629.

[11] Ji X, Meng R, Zhou J, Ling F, Jia J. Dynamic change of coagulation and anticoagulation markers of patients with acute cerebral infarction during intravenous urokinase thrombolysis. Neurological Res 2013;28:46–9.

[12] Wardlaw J. Thrombolysis for acute ischaemic stroke. Cochrane Database Sys Rev 2003:7.

[13] Ghadimi H, Boshehsari F, Allameh F, et al. Clinical characteristics, hospital morbidity and mortality, and up to 1-year follow-up events of acute myocardial infarction patients: the first report from Iran. Coronary Artery Dis 2006;17:585–91.

[14] Ding Z, Tong WC, Lu X-X, Peng H-P. Hyperbaric oxygen therapy in acute ischemic stroke: a review. Intervent Neurol 2014;2:201–11.

[15] Dominik S, Daniela F, Natalie T, et al. Mobilization of CD133+ progenitor cells in patients with acute cerebral infarction. Plos One 2014;9:e70796.

[16] Williams M, Patil S, Toledo EG, Vannemreddy P. Management of acute ischemic stroke: current status of pharmacological and mechanical endovascular methods. Neurological Res 2009;31:807–15.

[17] Wang BG, Yang N, Lin M, Lu B. Analysis of risk factors of hemorrhagic transformation after acute ischemic stroke: cerebral microbleeds do not correlate with hemorrhagic transformation. Cell Biochem Biophys 2014:70:135–42.

[18] Wardlaw JM, Warkow CP, Counsell C. Systematic review of evidence on thrombolytic therapy for acute ischaemic stroke. Lancet 1997;350:607–14.

[19] Bello LA, Smith SE, Vossough A, et al. Hemorrhagic transformation of childhood arterial ischemic stroke. Stroke 2011;42.

[20] Jorgensen L, Torvik A. Ischaemic cerebrovascular diseases in an autopsy series. 2. Prevalence, location, pathogenesis, and clinical course of cerebral infarcts. J Neurological Sci 1969;9:285–320.

[21] Ferro F M. Cardioembolic stroke: an update. Lancet Neurol 2003;2:177–88.

[22] Hepatic cirrhosis and intracranial hemorrhage: Significance of the association in 53 pathological cases. Ann Neurol 1980;8:204–5.

[23] Tian F, Liu G, Fan L, Chen Z, Liang Y. miR-21-3p alleviates neuronal apoptosis during cerebral ischemia-reperfusion injury by targeting SMAD2. Biocell 2021;45:49–56.

[24] Tan G, Lei C, Hao Z, Chen Y, Yuan R, Liu M. Liver function may play an even role in hemorrhagic transformation for stroke subtypes after acute ischaemic stroke. Eur J Neurol 2016;23:597–604.

[25] Ryu WS, Lee S-H, Kim CK, Kim BJ, Kwon H-M, Yoon B-W. High serum alkaline phosphatase in relation to cerebral small vessel disease. Atherosclerosis 2014;232:313–8.

[26] Campos F, Sobrino T, Ramos-Cabrero P, et al. High blood glutamate oxaloacetate transaminase levels are associated with good functional outcome in acute ischemic stroke. Journal of Cerebral Blood Flow & Metabolism Official Journal of the International Society of Cerebral Blood Flow & Metabolism 2011;31:1387–93.

[27] Senn R, Elkind MSV, Montaner J, Christ-Crain M, Katan M. Potential role of blood biomarkers in the management of nontraumatic intracerebral hemorrhage. Cerebrovasc Dis 2014;38:395–409.

[28] Campos F, Rodriguez-Yáñez M, Castellanos M, et al. Blood levels of glutamate oxaloacetate transaminase are more strongly associated with good outcome in acute ischemic stroke than glutamate pyruvate transaminase levels. Clin Sci 2011;121:11–7.

[29] Song Y, Wei C, Wang J. Upregulation of miR-143-3p attenuates oxidative stress-mediated cell ferroptosis in cardiomyocytes with atrial fibrillation by degrading glutamic-oxaloacetic transaminase 1. Biocell 2021;45:733–44.

[30] Pary BM, Anderson M, Kromnal RA, et al. The association between lipid levels and the risks of incident myocardial infarction, stroke, and total mortality: the Cardiovascular Health Study. J Am Geriatr Soc 2004;52:1639–47.

[31] Sturgeon JD, Folsom AR, Longstreth WT, Shahar E, Rosamond WD, Cushman M. Risk factors for intracerebral hemorrhage vs. ischemic vascular events: The Three-City Study. Stroke 2007;38:2718–25.

[32] Bonaventure A, Kurth T, Pico F, et al. Triglycerides and risk of hemorrhagic stroke vs. ischemic vascular events: The Three-City Study. Atherosclerosis 2010;210:243–8.

[33] Yamori Y, Nara Y, Horie R, Ooshima A. Abnormal membrane alkaline phosphatase and interventional urokinase thrombolysis for acute ischemic stroke. Int J Blood Flow & Metabolism Of 2011;31:1387–93.

[34] Konishi M, Iso H, Komachi Y, et al. Associations of serum total alkaline phosphatase and alanine transaminase levels. Clin Sci 2011;121:11–7.

[35] Dominik S, Daniela F, Natalie T, et al. Mobilization of CD133+ progenitor cells in patients with acute cerebral infarction. Plos One 2014;9:e70796.